Vtesse Pharma
Developed VTS-270 to treat patients with Niemann-Pick Disease Type C.
Launch date
Employees
Market cap
-
Enterprise valuation
€62—93m (Dealroom.co estimates Jul 2016.)
Gaithersburg Maryland (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$25.0m | Series A | ||
$25.0m | Series A | ||
$17.0m | Series A | ||
N/A | Acquisition | ||
Total Funding | €60.9m |
Recent News about Vtesse Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.